Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE DMH International
DMH International announces FDA approval of their medical imaging software, TouchPACS, created by their subsidiary Touch Medical Solutions.
CORAL SPRINGS, Fla., March 1, 2013 /PRNewswire/ -- DMH International (OTCBB: DMHI), announced that their wholly-owned subsidiary, Touch Medical Solutions, Inc (TMSI) has received approval from the United States Food and Drug Administration (US-FDA) for their medical imaging software suite, TouchPACS. The software is approved as a Class II medical device.
"The FDA approval has allowed for the immediate marketing of our PACS software," explained Rik J Deitsch, CEO of DMH International. "TouchPACS is now registered as a Class II medical device and can be sold to hospitals, clinics, radiology centers and physician offices for all of their imaging needs," he concluded.
TouchPACS is a cutting edge software suite for the PACS medical imaging market (Picture Archiving and Communications Systems). The market was valued at approximately $2.8 billion in 2010 and it is expected to grow to over $5.4 billion by 2017, according to MarketResearch.com, a research firm based out of Rockville, Md.
About DMH International.
DMH International, through it's subsidiary, Touch Medical Solutions, is a medical software and device company specializing in PACS (Picture Archiving and Communications Systems), EHR (Electronic Hospital records), EMR (Electronic Medical Records), PHR (Personal Health Records), Medical Transcription, and Paperless Medical Office Solutions. For additional information about Touch Medical Solutions, visit: http://www.dmhintl.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in DMH International's ("the Company's") business plan. The FDA approval of TouchPACS should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
©2012 PR Newswire. All Rights Reserved.